Intra-Cellular Therapies (ITCI) Reports Q4 Loss, Tops Revenue Estimates
1/3 14:55
Intra-Cellular Therapies (ITCI) came out with a quarterly loss of $1.05 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.76 per share a year ago. These figures are adjusted for non-recurring items....